Report of Foreign Issuer (6-k)
October 19 2016 - 3:49PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October, 2016
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On October 19, 2016, GW Pharmaceuticals plc (the “Company”),
issued a regulatory news service (“RNS”) announcement stating the Company’s intention to cancel the admission
of its 0.1 pence ordinary shares (Ordinary Shares) to trading on AIM on December 5, 2016. The last day of trading on AIM will be
December 2, 2016. The Company will retain its U.S. listing on the NASDAQ Global Market of its American Depositary Shares (ADSs)
under ticker symbol GWPH. Existing holders of ADSs do not need to take any action as a result of this announcement. The RNS is
attached as Exhibit 99.1 hereto and is incorporated by reference herein. In connection with the AIM delisting, the Company’s
Chairman delivered a letter to holders of the Company’s Ordinary Shares and the Company published a set of frequently asked
questions (FAQs) about the AIM delisting on the investor relations section of its website. The Chairman’s letter and FAQ’s
are attached as Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated by reference herein. The information contained
in Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 hereto shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
99.1 Regulatory news service announcement dated October
19, 2016
99.1 Chairman’s Letter to Holders of Ordinary
Shares dated October 19, 2016
99.1 AIM Delisting Frequently Asked Questions published
October 19, 2016
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: October 19, 2016
|
|
|